Use of DPP-4 inhibitors in type 2 diabetes: Focus on sitagliptin

Diabetes, Metabolic Syndrome and Obesity

Volumn 3, Issue , 2010, Pages 31-41

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Sitagliptin; Treatment; Type 2 diabetes

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBIGLUTIDE; ANTIDIABETIC AGENT; EXENDIN 4; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LIXISENATIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ADD ON THERAPY; ANGINA PECTORIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STRUCTURE ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 77953472148     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s7327     Document Type: Review

References (80)

1. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin. 2003;19:635-641
2. Skyler JS, Bergenstal R, Bonow RO, et al Intensive glycemic control and the prevention of vardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53:298-304
3. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203
4. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358:739-746
5. Hsia SH, Davidson MB. Established therapies for diabetes mellitus. Curr Med Res Opin. 2002;18: Suppl 1:S13-S21
6. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004;64:1339-1358
7. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63:1373-1405
8. Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Austr. 2004;181:536-539
9. Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48:1700-1713
10. Lehy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005;36:197-209
11. Wajchenberg BL. ß-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187-218
12. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA. 2002;287:360-372
13. Bailey CJ. Drugs on the horizon for diabesity. Curr Diab Rep. 2005;5:353-359
14. Ahrén B. Exenatide: a novel treatment of type 2 diabetes. Therapy. 2005;2:207-222
15. Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes. Drugs. 2009;69:1985-2004
16. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705
17. Ahrén B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays. 1998;20:642-651
18. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21:517-533
19. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care. 2007;30:1344-1350
20. Ahrén B: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab. 2009;23: 487-498
21. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89: 2078-2084
22. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28:1936-1940
23. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249-1255
24. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care. 2002;25:869-875
25. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabet Obes Metab. 2007;9:186-193
26. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol. 2009;623:148-154
27. Ahrén B, Sörhede Winzell M, Wierup N, et al. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell specific overexpression of human islet amyloid polypeptide. Regul Pept. 2007;143:97-103
28. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl-5,6-dihy dro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-151
29. Herman GA, Stevens C, van Dyck K, et al. Pharmacokinetic and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78:675-688
30. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612-4619
31. Bergman A, Ebel D, Liu F, et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007;28:315-322
32. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the DPP-4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos. 2007;35:533-538
33. Bergman AJ, Steven C, Zhou, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase IV inhibitor: a double-blind randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55-72
34. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876-886
35. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea. Diab Res Clin Pract. 2009;83:106-116
36. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabet Res Clin Pract. 2008;79:291-298
37. Kadowaki T, Tajima N, Odawara M, Nishi M, Nonaka K, Stein PP. Sitagliptin added to ongoing treatrment with metformin improved glycemic control and was well tolerated in Japenese patients with type 2 diabetes. Diabetes. 2008;Suppl 1:A589-590
38. Nonaka K, Tsubouchi H, Okuyama K, Fukao Y, Johnson-Levonas AO, Amatruda JM. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res. 2009;41:232-237
39. Kashiwagi A, Tajima N, Kadowaki T, et al. Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes. Diabetes. 2008; Suppl 1:A590
40. Tajima N, Kadowaki T, Odawara M, Nishi M, Nonaka K, Stein PP. Sitagliptin added to ongoing treatment with glimepiride improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes. Diabetes. 2008;57:Suppl 1:A589 41.
41. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams- Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637
42. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-25671
43. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-1987
44. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inad-equately controlled with metformin alone. Diabetes Care. 2006;29: 2638-2643
45. Scott R, Wu L, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61: 171-180
46. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabet Obes Metab. 2007;9:733-745
47. Rosenstock J, Brazg RG, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Ther. 2006;28:1556-1568
48. Alba M, Sheng D, Guan Y, et al. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin. 2009;25:2507-2514
49. Aaboe K, Vilsbøll T, Knop FK, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, improves the insulin secreting capacity of the ß-cells in subjects with type 2 diabetes mellitus: a randomized trial. Diabetes. 2009; Suppl 1:A163
50. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23: 1329-39
51. Qi DS, Teng R, Jiang M, et al. Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycaemic control in patients with type 2 diabetes. Diabetologia. 2008;51:Suppl 1:S36
52. Chan JCN, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insuf-ficiency. Diabetes Obes Metab. 2008;10:545-555
53. Barzilai N, Mahoney EM, Guo H, et al. Sitagliptin is well tolerated and leads to rapid improvement in blood glucose the first days of mono-therapy in patients aged 65 years and older with TDM. Diabetes. 2009; Suppl 1:A158
54. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inad-equately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabet Obes Metab. 2007;9:194-205
55. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959-969
56. Vilsbøll T, Rosenstock JM, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167-177
57. Arjona Ferreira JC, Dobs A, Goldstein BJ, et al. Triple combination therapy with sitagliptin, metformin and rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetologia. 2008;51:Suppl 1: S365
58. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosglitazone monotherapy in patients with type 2 diabetes: a 24-week double-blind, randomized trial. Diabetes Care. 2007;30:217-223
59. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes comperaed with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611-622
60. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315-2317
61. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week randomized, double-blind study. Diabet Obes Metab. 2008;10:82-90
62. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649-1655
63. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46-55
64. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glucaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabet Obes Metab. 2007;9: 166-174
65. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-4819
66. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blond, placebo-controlled study. Curr Med Res Opin. 2009;25: 2361-2371
67. Garber AJ, Foley JE, Banerhi MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabet Obes Metab. 2008;10:1047-1056
68. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chane R. Saxagliptin added to submaximal dose of sulphonylurea improves glucaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract. 2009;63:1395-1406
69. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabet Obes Metab. 2009;11:167-176
70. Williams-Herman D, Round E, Swern A, et al. Safety and tolerability of sitagliptin in patients with type 12 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14
71. Dore DD, Seeger JD, Arnold Chan K. Use of claims-based active drug safety surveillance system to assess the risk of acute pancteatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027
72. de Heer J, Holst JJ. Sulphonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007;56:438-443
73. Ahrén B, Schweizer A, Dejager S, et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:11236-1243
74. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metabol. 2009;11:157-166
75. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:541-559
76. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8:369-385
77. Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obese Metab. 2008;10 Suppl 1:43-55
78. www.clinicaltrials.gov (NCT00790205). Accessed February 18, 2010
79. Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract. 2008;62: Suppl 159:8-14
80. Carr RD, Larsen MO, Sörhede Winzell M, et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol. 2008;295:E779-E784.